Literature DB >> 17220874

Foxp3-dependent programme of regulatory T-cell differentiation.

Marc A Gavin1, Jeffrey P Rasmussen, Jason D Fontenot, Valeria Vasta, Vincent C Manganiello, Joseph A Beavo, Alexander Y Rudensky.   

Abstract

Regulatory CD4+ T cells (Tr cells), the development of which is critically dependent on X-linked transcription factor Foxp3 (forkhead box P3), prevent self-destructive immune responses. Despite its important role, molecular and functional features conferred by Foxp3 to Tr precursor cells remain unknown. It has been suggested that Foxp3 expression is required for both survival of Tr precursors as well as their inability to produce interleukin (IL)-2 and independently proliferate after T-cell-receptor engagement, raising the possibility that such 'anergy' and Tr suppressive capacity are intimately linked. Here we show, by dissociating Foxp3-dependent features from those induced by the signals preceding and promoting its expression in mice, that the latter signals include several functional and transcriptional hallmarks of Tr cells. Although its function is required for Tr cell suppressor activity, Foxp3 to a large extent amplifies and fixes pre-established molecular features of Tr cells, including anergy and dependence on paracrine IL-2. Furthermore, Foxp3 solidifies Tr cell lineage stability through modification of cell surface and signalling molecules, resulting in adaptation to the signals required to induce and maintain Tr cells. This adaptation includes Foxp3-dependent repression of cyclic nucleotide phosphodiesterase 3B, affecting genes responsible for Tr cell homeostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220874     DOI: 10.1038/nature05543

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  481 in total

Review 1.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells.

Authors:  Xuguang Tai; François Van Laethem; Leonid Pobezinsky; Terry Guinter; Susan O Sharrow; Anthony Adams; Larry Granger; Michael Kruhlak; Tullia Lindsten; Craig B Thompson; Lionel Feigenbaum; Alfred Singer
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

3.  B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis.

Authors:  Keith M Hamel; Yanxia Cao; Susan Ashaye; Yumei Wang; Robert Dunn; Marilyn R Kehry; Tibor T Glant; Alison Finnegan
Journal:  J Immunol       Date:  2011-09-23       Impact factor: 5.422

Review 4.  Molecular and functional heterogeneity of T regulatory cells.

Authors:  Lequn Li; Vassiliki A Boussiotis
Journal:  Clin Immunol       Date:  2011-08-30       Impact factor: 3.969

Review 5.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity.

Authors:  Thomas R Malek; Iris Castro
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

Review 6.  The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer.

Authors:  Frances Mercer; Derya Unutmaz
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

7.  Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells.

Authors:  Weiming Ouyang; Omar Beckett; Qian Ma; Ji-hye Paik; Ronald A DePinho; Ming O Li
Journal:  Nat Immunol       Date:  2010-05-13       Impact factor: 25.606

Review 8.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

9.  FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis.

Authors:  F Sellebjerg; M Krakauer; M Khademi; T Olsson; P S Sørensen
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

10.  Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents.

Authors:  A Picchianti Diamanti; M M Rosado; M Scarsella; V Germano; E Giorda; S Cascioli; B Laganà; R D'Amelio; R Carsetti
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.